way 100135 has been researched along with anandamide in 1 studies
Studies (way 100135) | Trials (way 100135) | Recent Studies (post-2010) (way 100135) | Studies (anandamide) | Trials (anandamide) | Recent Studies (post-2010) (anandamide) |
---|---|---|---|---|---|
143 | 0 | 34 | 2,566 | 29 | 957 |
Protein | Taxonomy | way 100135 (IC50) | anandamide (IC50) |
---|---|---|---|
Fatty-acid amide hydrolase 1 | Homo sapiens (human) | 3.75 | |
Potassium channel subfamily K member 3 | Homo sapiens (human) | 3 | |
Potassium channel subfamily K member 2 | Bos taurus (cattle) | 1 | |
Transient receptor potential cation channel subfamily V member 2 | Rattus norvegicus (Norway rat) | 4.78 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abe, K; Egashira, N; Fujiwara, M; Hayakawa, K; Ikeda, T; Iwasaki, K; Mishima, K | 1 |
1 other study(ies) available for way 100135 and anandamide
Article | Year |
---|---|
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism.
Topics: Animals; Arachidonic Acids; Cannabidiol; Cerebral Infarction; Cerebrovascular Circulation; Endocannabinoids; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperazines; Polyunsaturated Alkamides; Receptor, Serotonin, 5-HT1A; Resorcinols; Serotonin 5-HT1 Receptor Antagonists; Serotonin Antagonists | 2005 |